Rapid Micro Biosystems, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 1, 2024. This is an annual report, not a standalone fourth-quarter filing.
Business context
Rapid Micro Biosystems develops and sells the Growth Direct platform, which automates microbial quality-control testing for pharmaceutical manufacturing. Revenue comes from systems, proprietary consumables, software, validation and field services, and service contracts. At year-end, the company reported 141 systems placed at 40 customers; 121 systems were validated. Recurring revenue is generated mainly by consumables and service contracts.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $22.5 million | $17.1 million |
| Product revenue | $14.8 million | $11.1 million |
| Service revenue | $7.7 million | $6.1 million |
| Gross margin | (24.4)% | (49.8)% |
| Operating loss | $56.6 million | $63.2 million |
| Net loss | $52.5 million | $60.8 million |
| Net loss per share, basic and diluted | $1.22 | $1.43 |
| Net cash used in operating activities | $45.1 million | $58.5 million |
Recurring product and service revenue was $13.5 million, up 23.3%, and represented 60.2% of total revenue, compared with 64.1% in 2022. Cash, cash equivalents and investments totaled $95.0 million at year-end ($95.2 million including restricted cash). Current assets were $120.4 million and current liabilities were $19.0 million. Total liabilities were $25.5 million, including lease liabilities; the filing does not report outstanding borrowings as debt. Operating lease payments were $3.7 million and Lexington sublease payments were $4.2 million over their respective remaining terms.
Management said available cash, cash equivalents and investments were expected to fund operating expenses and capital expenditures for at least 12 months after the financial statements were issued. The company reported no committed external source of funds. It established an at-the-market equity facility; the agreement permits up to $50 million in aggregate sales, while the filed prospectus permits sales of up to $10 million. No shares had been sold under the facility through the filing date.
Material changes versus FY2022
- Revenue increased 31.4%, supported by 16 system placements versus 9 in 2022 and higher consumable and service-contract revenue.
- Gross margin improved by 25.4 percentage points but remained negative, as costs of product and service revenue exceeded revenue.
- Operating cash use fell by $13.5 million, primarily due to working-capital and inventory management, payment timing, and lower inventory purchases.
- Research and development expense was broadly flat; sales and marketing expense fell 11.2%, and general and administrative expense fell 7.0%, including lower legal and investor-relations costs after the 2022 strategic review.
- Interest income rose to $4.2 million from $1.8 million, reflecting higher rates. Net losses continued, and accumulated deficit reached $428.4 million.
Outlook, risks and unusual items
- No specific FY2024 revenue, earnings or cash-flow guidance is provided in the filing. Management expects continued losses and investment in commercial expansion, manufacturing, research and development, and product development.
- The company was preparing a rapid automated sterility test for commercial launch by mid-2024. Management projected organism detection in as little as 12 hours and final results in one to three days; these are expected product performance claims, not reported commercial results.
- Key risks include continued losses and cash consumption, uncertain customer adoption and sales cycles, reliance on Growth Direct and recurring consumable demand, negative gross margins, and the possibility of needing additional capital.
- Manufacturing also depends on third-party suppliers, including single-source components. The camera used in Growth Direct had been discontinued; the company said it had inventory while qualifying a replacement supplier.
- The Thermo Fisher patent license was due to expire in April 2024. The filing describes the expiration date but does not establish the subsequent status of the license.
- On February 2, 2024, Nasdaq notified the company that its share price had been below the $1 minimum bid for 30 consecutive business days. The compliance period ran through July 31, 2024; the company said a reverse stock split could be considered.
- The company reported no material litigation, no material cybersecurity incident identified, and effective disclosure controls and internal control over financial reporting as of year-end. Its auditor issued an unqualified opinion on the financial statements and was not engaged to audit internal controls.
Important facts for investors to verify
- Subsequent quarterly filings: revenue growth, system placements and validations, consumable utilization, and progress toward positive gross margins.
- Cash burn and runway against management’s 12-month estimate, including any ATM sales, new financing, or changes in spending.
- Commercial launch and customer adoption of the rapid sterility test, including independently supportable performance and revenue contribution.
- Resolution of the Nasdaq minimum-bid-price deficiency and current listing status.
- Outcome of the Thermo Fisher license expiration and qualification of the replacement camera supplier.
- Customer and receivables concentration: one customer represented 16.5% of 2023 revenue, and several customers represented significant portions of year-end receivables.